Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]

Latest in novel approaches to CLL and MCL

Professor Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK

Latest in novel approaches to CLL and MCL ( Professor Peter Hillmen - Leeds Teaching Hospitals NHS Trust, Leeds, UK )

Comment: Metastatic triple-negative breast cancer responds to immunotherapy

Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA

Comment: Metastatic triple-negative breast cancer responds to immunotherapy ( Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA )

Real-world targeted treatment based on whole genome sequencing difficult in...

Dr Lorraine Chantrill - Garvan Institute of Medical Research, Darlinghurst...

Real-world targeted treatment based on whole genome sequencing difficult in pancreatic cancer ( Dr Lorraine Chantrill - Garvan Institute of Medical Research, Darlinghurst, Australia )

Comment: Research developments stir hopes for melanoma

Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA

Comment: Research developments stir hopes for melanoma ( Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA )

New T cell–based immunotherapy shows promise for lethal stem cell transplant...

Dr Susan Prockop - Memorial Sloan Kettering Cancer Center, New York, USA

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication ( Dr Susan Prockop - Memorial Sloan Kettering Cancer Center, New York, USA )

Investigational PD-L1–targeted immunotherapy safe for patients with triple...

Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer ( Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )

Pembrolizumab found to be safe with durable responses in advanced non-small...

Dr Edward Garon - David Geffen School of Medicine at the University of...

Pembrolizumab found to be safe with durable responses in advanced non-small cell lung cancer ( Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA )

PARP inhibitor combo shows early promise for patients with and without BRCA...

Dr Timothy Yap - Royal Marsden Hospital, London, UK

PARP inhibitor combo shows early promise for patients with and without BRCA mutations ( Dr Timothy Yap - Royal Marsden Hospital, London, UK )

Phase III trial shows pembrolizumab preferable to ipilimumab in advanced...

Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Phase III trial shows pembrolizumab preferable to ipilimumab in advanced melanoma ( Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

New immunotherapy yields long-lasting responses in some patients with advanced...

Dr Mark Middleton - University of Oxford, Oxford, UK

New immunotherapy yields long-lasting responses in some patients with advanced melanoma ( Dr Mark Middleton - University of Oxford, Oxford, UK )

What are the objectives for CART-meso immunotherapy?

Dr Janos Tanyi - University of Pennsylvania, Philadelphia, USA

What are the objectives for CART-meso immunotherapy? ( Dr Janos Tanyi - University of Pennsylvania, Philadelphia, USA )

More from ecancer